KRAS and lung cancer: However, only the study of KRAS G12C mutation has made a breakthrough with a specific inhibitor AMG510 (Sotorasib) approved by FDA [25] and MRTX849 (Adagrasib) ongoing clinical trials [26], and the limited success just benefits to a very small number of lung cancer patients [27].